{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:50:53Z","timestamp":1792803053819,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacc.2025.08.017","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:10:01Z","timestamp":1756282201000},"page":"2418-2433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"86","author":[{"given":"Milind Y.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-9266","authenticated-orcid":false,"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edileide","family":"de Barros Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Zorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Verheyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Meder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-3403","authenticated-orcid":false,"given":"Olga","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Suryawanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Florea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali T.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.jacc.2025.08.017_bib1","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2025.08.017_bib2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.jacc.2025.08.017_bib3","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.08.017_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10253","key":"10.1016\/j.jacc.2025.08.017_bib5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jacc.2025.08.017_bib6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2025.08.017_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM Study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.jacc.2025.08.017_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacc.2025.08.017_bib9","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"25","key":"10.1016\/j.jacc.2025.08.017_bib10","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.08.017_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"10293","key":"10.1016\/j.jacc.2025.08.017_bib12","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacc.2025.08.017_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017185","article-title":"Serial changes in ventricular strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from the VALOR-HCM Trial","volume":"17","author":"Desai","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.jacc.2025.08.017_bib14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacc.2024.06.025","article-title":"Mavacamten in obstructive hypertrophic cardiomyopathy patients referred for septal reduction: health status analysis through week 56 in VALOR-HCM trial","volume":"84","author":"Desai","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2025.08.017_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"issue":"47","key":"10.1016\/j.jacc.2025.08.017_bib16","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacc.2025.08.017_bib17","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai","year":"2025","journal-title":"Circ J"},{"issue":"32","key":"10.1016\/j.jacc.2025.08.017_bib18","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","article-title":"Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy","volume":"34","author":"Coats","year":"2013","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.jacc.2025.08.017_bib19","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.017_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pcad.2022.08.002","article-title":"Prognostic value of age-sex adjusted NT-proBNP ratio in obstructive hypertrophic cardiomyopathy","volume":"74","author":"Hutt","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.jacc.2025.08.017_bib21","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/ehf2.14073","article-title":"Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis","volume":"9","author":"Jansen","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10.1016\/j.jacc.2025.08.017_bib22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1253\/circj.CJ-10-0782","article-title":"Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy","volume":"75","author":"Kubo","year":"2011","journal-title":"Circ J"},{"issue":"23","key":"10.1016\/j.jacc.2025.08.017_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027618","article-title":"Circulating biomarkers in hypertrophic cardiomyopathy","volume":"11","author":"Matthia","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"10.1016\/j.jacc.2025.08.017_bib24","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.017_bib25","unstructured":"Desai M. Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. New England Journal of Medicince. doi:NEJMdo008147"},{"issue":"2","key":"10.1016\/j.jacc.2025.08.017_bib26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy: design, rationale, and baseline characteristics of ODYSSEY-HCM","volume":"13","author":"Desai","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"25","key":"10.1016\/j.jacc.2025.08.017_bib27","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacc.2025.08.017_bib28","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"90","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2025.08.017_bib29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"10.1016\/j.jacc.2025.08.017_bib30","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1093\/eurheartj\/ehae590","article-title":"Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial","volume":"45","author":"Coats","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacc.2025.08.017_bib31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjcard.2013.04.060","article-title":"Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy","volume":"112","author":"Kawasaki","year":"2013","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.jacc.2025.08.017_bib32","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jacc.2013.03.055","article-title":"Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy","volume":"62","author":"Kubo","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"10.1016\/j.jacc.2025.08.017_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7622","article-title":"Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients","volume":"9","author":"Nag","year":"2023","journal-title":"Sci Adv"},{"issue":"21","key":"10.1016\/j.jacc.2025.08.017_bib34","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","article-title":"Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy","volume":"83","author":"Maron","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2025.08.017_bib35","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00228-024-03660-2","article-title":"Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials involving 2624 patients","volume":"80","author":"Tanashat","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jacc.2025.08.017_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcmg.2013.08.010","article-title":"Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes","volume":"7","author":"Desai","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"21","key":"10.1016\/j.jacc.2025.08.017_bib37","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacc.2025.08.017_bib38","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jtcvs.2020.12.016","article-title":"Latent outflow tract obstruction in hypertrophic cardiomyopathy: clinical characteristics and outcomes of septal myectomy","volume":"164","author":"Cui","year":"2022","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725074315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725074315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:04:42Z","timestamp":1769202282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725074315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0735109725074315"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.017","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}